Urogen Pharma (NASDAQ:URGN) Issues Earnings Results, Beats Estimates By $0.12 EPS

Urogen Pharma (NASDAQ:URGN) released its quarterly earnings data on Friday. The company reported ($1.08) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.12, Bloomberg Earnings reports. The business had revenue of $0.02 million during the quarter.

NASDAQ:URGN traded down $0.55 during trading hours on Friday, reaching $32.08. 163,935 shares of the stock were exchanged, compared to its average volume of 157,343. The stock has a 50-day simple moving average of $33.40. Urogen Pharma has a twelve month low of $30.48 and a twelve month high of $55.49. The stock has a market cap of $453.66 million, a P/E ratio of -6.68 and a beta of 1.21.

Large investors have recently added to or reduced their stakes in the business. Public Employees Retirement Association of Colorado acquired a new position in Urogen Pharma during the first quarter worth $41,000. Bank of Montreal Can acquired a new position in Urogen Pharma during the second quarter worth $56,000. Harel Insurance Investments & Financial Services Ltd. lifted its stake in Urogen Pharma by 100.0% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,000 shares of the company’s stock worth $74,000 after purchasing an additional 1,000 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Urogen Pharma by 112.6% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,421 shares of the company’s stock worth $89,000 after purchasing an additional 1,282 shares in the last quarter. Finally, JPMorgan Chase & Co. acquired a new position in Urogen Pharma during the second quarter worth $170,000. Institutional investors own 97.70% of the company’s stock.

A number of research analysts recently commented on the company. Cowen reiterated a “buy” rating on shares of Urogen Pharma in a report on Monday, May 6th. Zacks Investment Research cut Urogen Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, July 30th. JPMorgan Chase & Co. assumed coverage on Urogen Pharma in a report on Thursday, May 30th. They issued a “neutral” rating and a $41.00 price objective on the stock. ValuEngine upgraded Urogen Pharma from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Goldman Sachs Group assumed coverage on Urogen Pharma in a report on Wednesday, May 29th. They issued a “neutral” rating and a $50.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $59.00.

About Urogen Pharma

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

See Also: Trading on Margin

Earnings History for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.